Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

31.08 -1.30 (-4.01%)
Official Closing Price Updated: 4:15 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 Next >
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From Legend Biotech USA Inc.
Via GlobeNewswire
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
Newly created position to lead efforts focused on continued growth and sales 
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader 
From Legend Biotech USA Inc.
Via GlobeNewswire
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
From Legend Biotech USA Inc.
Via GlobeNewswire
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis 
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
From Legend Biotech Corporation
Via Business Wire
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
From Legend Biotech Corporation
Via Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.